RATIONALE: S100B is an astrocytic, calcium-binding protein which in nanomolar concentrations has neuroprotective and regenerating effects on neurons and glial cells. Increased levels have been shown to be positively correlated with therapeutic response in major depression. Event-related potentials (ERP) have been reported to be impaired in depressed patients. OBJECTIVES: The aim of our study was to assess the relationship between S100B and visually evoked ERP in depression. METHODS: ERP and S100B serum concentration were studied in 18 patients with major depression, before and after 4 weeks of antidepressant treatment. RESULTS: The S100B concentration in patients was increased at intake and after 4 weeks of treatment compared to healthy controls. Initially increased P3-latency normalized and P2-latency significantly decreased after 4 weeks of treatment, although only in patients with clearly elevated initial S100B levels (mean plus 2 SD of the healthy controls). CONCLUSION: The neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.
RATIONALE: S100B is an astrocytic, calcium-binding protein which in nanomolar concentrations has neuroprotective and regenerating effects on neurons and glial cells. Increased levels have been shown to be positively correlated with therapeutic response in major depression. Event-related potentials (ERP) have been reported to be impaired in depressedpatients. OBJECTIVES: The aim of our study was to assess the relationship between S100B and visually evoked ERP in depression. METHODS: ERP and S100B serum concentration were studied in 18 patients with major depression, before and after 4 weeks of antidepressant treatment. RESULTS: The S100B concentration in patients was increased at intake and after 4 weeks of treatment compared to healthy controls. Initially increased P3-latency normalized and P2-latency significantly decreased after 4 weeks of treatment, although only in patients with clearly elevated initial S100B levels (mean plus 2 SD of the healthy controls). CONCLUSION: The neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.
Authors: R Machado-Vieira; D R Lara; L V C Portela; C A Gonçalves; J C Soares; F Kapczinski; D O Souza Journal: Eur Neuropsychopharmacol Date: 2002-06 Impact factor: 4.600
Authors: D R Lara; C S Gama; P Belmonte-de-Abreu; L V Portela; C A Gonçalves; M Fonseca; S Hauck; D O Souza Journal: J Psychiatr Res Date: 2001 Jan-Feb Impact factor: 4.791
Authors: Detlef E Dietrich; Ute Hauser; Marion Peters; Yuanyuan Zhang; Martin Wiesmann; Mark Hasselmann; Sebastian Rudolf; Oliver Jüngling; Holger Kirchner; Thomas F Münte; Volker Arolt; Hinderk M Emrich; Sönke Johannes; Matthias Rothermundt Journal: Neurosci Lett Date: 2004-01-02 Impact factor: 3.046
Authors: Francesco Benedetti; Sara Poletti; Thomas A Hoogenboezem; Clara Locatelli; Oliver Ambrée; Harm de Wit; Annemarie J M Wijkhuijs; Elena Mazza; Chiara Bulgarelli; Benedetta Vai; Cristina Colombo; Enrico Smeraldi; Volker Arolt; Hemmo A Drexhage Journal: J Neuroimmune Pharmacol Date: 2016-04-23 Impact factor: 4.147
Authors: Ricard Navinés; Giovanni Oriolo; Igor Horrillo; Myriam Cavero; Bruno Aouizerate; Martin Schaefer; Lucile Capuron; J Javier Meana; Rocio Martin-Santos Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678